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S208 Poster Session Imorning on collection one hour prior to the collection time. All
patients received 0.24mg/kg/day of Plerixafor. There were no side
effects observed. Only one of the patients required a second dose
of Plerixafor and five patients had not reach the required CD34
count of 4  106 cells/kg.
Conclusions: Plerixafor was used at The London Clinic recently
with favourable outcomes. The target for all cases was CD341 cells
4  106 cells/kg recipient body weight. Two patients responded ex-
tremely well with a CD341 count of 21.79  106 cells/kg and 15.16
 106 cells/kg achieved. Three patients had a poor outcomes, where
the collection was below 3  106 cells/kg of CD341 count was col-
lected. The other seven patients met the target required of CD341
count of 4  106 cells/kg or above.
According to this study Plerixafor has improved PBSC outcome
with seven patients out of 12 in this study.
Due to the small numbers this study it is thus far inconclusive but
it would be sensible to say Prelixafor made a difference for our 11 pa-
tients. An Ongoing study with new patient experiences is needed.
More than one dose of Plerixafor was required for heavily pre-treated
patients who are historically poor mobiliser of PBSC.147
ANALYSIS OF TOXICITY PROFILE OF CBV VS BEAM IN LYMPHOMA
PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT – A SINGLE
INSTITUTION RETROSPECTIVE REVIEW
Khalife, M., Neme, K., Janakiraman, N. Henry Ford Hospital, Detroit,
MI
Introduction: Several preparative regimens are used in Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients prior
to autologous hematopoietic stem cell transplant (HSCT). These in-
clude CBV (cylophosphamide, etoposide and carmustine), BEAM
(carmustine, etoposide, cytarabine andmelphalan) or TBI based reg-
imens. This study retrospectively compares the toxicities of CBV vs
BEAM in lymphoma post-HSCT in our institution.
Methods: We retrospectively reviewed the charts of 77 lymphoma
patients who underwent autologous HSCT between 1999 and
2010. 35 patients received CBV between 1999 and 2005 (11 HL
and 24 NHL) and 42 patients received BEAM between 1999 and
2010 (12 HL and 30 NHL). CBV consisted of cyclophosphamide
7200 mg/m2, etoposide 1600 mg/m2, and carmustine 300 mg/m2.
BEAM consisted of carmustine 300 mg/m2, etoposide 1600 mg/
m2, cytarabine 1600 mg/m2, and melphalan 140 mg/m2. Lung toxic-
ity was defined as a 15% drop in adjusted DLCO (carbon monoxide
diffusing capacity) on pulmonary function test (PFT) or respiratory
symptoms requiring steroids within six weeks post-HSCT. Clini-
cally significant lung toxicity was defined as respiratory symptoms
requiring steroids or leading to death.
Results: Lung toxicity occurred in 10/42 (23.8%) of BEAM and
13/35 (37.1%) of CBV patients (p 5 0.203). However, clinically
significant lung toxicity occurred only in 3/42 (7.1%) of BEAM
(one of which was lethal) and only in 1/35 (2.9%) of CBV patients
(p 5 0.621). All 4 clinically significant lung toxicities occurred in
HL. Cardiac toxicities were comparable (11.9% after BEAM vs
8.6% after CBV; p 5 0.722). Time to engraftment defined as
neutrophil . 500 (12.9 days after CBV vs 11.3 days after
BEAM; p 5 0.031), diarrhea (65.7% after CBV vs 31.0% after
BEAM; p 5 0.002) and infections requiring intravenous antibi-
otics (60.0% after CBV vs 14.3% after BEAM; p\ 0.001) were
higher after CBV. Severe mucositis requiring parenteral nutrition
was comparable (21.4% after BEAM and 14.3 after CBV p 5
0.418).
Conclusion: HL patients, especially those who received BEAM,
appear to be at higher risk of clinically significant lung toxicity
compared to NHL patients. Prior bleomycin may have contrib-
uted to this. Most patients who had a 15% decline in DLCO
post HSCT did not experience clinically significant lung toxicity.
Therefore, the value of post HSCT PFT is unclear and close
monitoring of high risk patients for symptoms is warranted.
Finally, the time to engraftment and other toxicities favored
BEAM.148
G-CSF DOSE ESCALATION STARTING DAY 8 AFTER SALVAGE RICE
CHEMOTHERAPY RESULTS IN ADEQUATE AND PREDICTABLE AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN RELAPSED/
REFRACTORY LYMPHOMA
Weber, A.M., Pillai, P., Styler, M.J., Mullaney, R., Topolsky, D.,
Ward, K.M., Crilley, P. Hahnemann University Hospital, Philadelphia,
PA
Introduction: Optimal dosing and timing of G-CSF for stem cell
mobilization after salvage RICE (Rituximab, Ifosfamide, Carbopla-
tin, and Etoposide) for relapsed/refractory lymphoma is unclear.
Common G-CSF regimens have doses ranging from 5-16 mcg/kg/
d starting one to several days after chemotherapy until a predeter-
mined variable is reached to initiate peripheral blood stem cell
collection.
Patients and Methods: We performed a retrospective analysis of
stem cell collection with G-CSF after salvage RICE for consecutive
patients with relapsed/refractory lymphoma at our center. Our earlier
practice was augmenting stem cell mobilization with 16 mcg/kg/
d G-CSF from Day 1 to final day of collection to achieve WBC .
10,000/mm3 prior to initiating stem collection (Standard dose group).
We observed difficulties in terms of adequacy and timing of collection
with this method. We modified the regimen to G-CSF at 5 mcg/kg/
d from Day 1 to 7, followed by dose escalation to 16 mcg/kg/d on
Day 8 until final day of collection, and a planned peripheral blood
stem collection beginning Day 12 (Dose escalation group).
Results: Standard dose group: Three patients (2 DLBCL, 1 Hodg-
kin’s lymphoma) received salvage RICE for 2 to 3 cycles. Peripheral
blood stem cell collection resulted in CD341 yields of only 0.3 to 3.0
x106 per kg in 5 to 6 apheresis sessions initiated between day 11 and
day 16.
Dose escalation group: Four patients (2 DLBCL, 1 T cell rich B
cell lymphoma, 1 Hodgkin’s lymphoma) received salvage RICE for
2 to 4 cycles. Peripheral blood stem cell collection resulted in
more than sufficient CD341 yields (all . 3x106 per kg, range 3.80
to 7.10 x106) in only 1 to 3 apheresis sessions initiated on day 12.
Conclusion: A timed escalation to high dose G-CSF on day 8 sal-
vage RICE chemotherapy for relapsed/refractory lymphoma re-
sulted in superior CD341 cells for collection with fewer apheresis
requirements and a predictable apheresis start day.149
OPTIMIZING THE EFFICACY OF PLERIXAFOR AS A SALVAGE OPTION
IN POOR MOBILIZERS FOLLOWING CHEMOTHERAPY PLUS G-CSF
MOBILIZATION
Kochuparambil, S.T.1, Mebel, E.R.3, DeRemer, D.L.2, Jillella, A.P.1,
Awan, F.T.1 1Medical College of Georgia, Augusta, GA; 2Medical College
of Georgia, Augusta, GA; 3University of PittsburghMedical Center, Pitts-
burgh, PA
Introduction: Recent data of the combination of G-CSF (G) with
Plerixafor (P) has established its efficacy in stem cell mobilization
for autologous transplants. However, there is limited data about
the utility of plerixafor in patients who are beingmobilized with che-
motherapy and G.
Methods: In this study we describe our experience with the use of
plerixafor as a salvage option in 12 patients (6 Non-Hodgkin Lym-
phoma, 3 Multiple Myeloma, 2 Hodgkin Lymphoma, 1 Ewings
Sarcoma) who fail to optimally mobilize CD341 cells (\ 10
CD341 cells/ul at neutrophil recovery) after G. Patients received
Cyclophosphamide (CY) (3-4 g/m2) followed by G (10 mcg/kg)
from D1 to D10. Data was collected on mobilization and transplant
outcomes and analyzed utilizing SPSS version 13.0.
Results: The median age was 60 years (range 18-76). 75% were
males. Patients had received a median of 2 lines of therapy (range
1-3) prior to stem cell mobilization. Following failure to mobilize
with G post CY, at neutrophil recovery patients received a median
of 2.5 doses of P (range 1-8). The average number of apheresis ses-
sions was 4.2 and the total number of CD341 stem cells collected
was 4.0x106/kg. Utilizing a cut-off of 2x106 CD341/kg, one patient
who received P had an unsuccessful harvest. ThreeNHLpatients re-
quired. 4 doses of P, but all eventually collected. 2 106 CD341
